The highly specialised technologies (HST) process was introduced in 2013 for the purpose of evaluati...
Read moreCell and gene therapies - life saving opportunity for many patients
Read moreThis resolution includes proposed reforms to the market access (including pricing) landscape designe...
Read moreThis study investigates costs of gene/acute therapies versus chronic treatments for rare diseases, o...
Read moreFollowing a series of FOI requests to CCGs, MTG said a number of CCGs are currently restricting acce...
Read moreNHS England’s cost-effectiveness watchdog, (NICE), issued a first draft document saying that it di...
Read moreFaster access to new treatments for very rare conditions announced following a revised decision maki...
Read moreThe development of gene therapies represents a new frontier of science, with the potential to help p...
Read moreThis study investigates the efficiency of the new CDF appraisal process for indications without prio...
Read more